Abstract:Background. Pancreatic ductal adenocarcinoma (PDAC) displays a typical mucin expression pattern which is characterized by MUC1 positive, MUC2 negative, and MUC5AC positive. More and more evidences show that mucins are involved in the development of pancreatic diseases. However, the relationship between mucin expression and prognosis of PDAC patients has been controversial in the past decades; therefore, we aim to figure out the association of mucin expression with survival in PDAC patients who underwent radical resection. Methods. We performed immunohistochemistry (IHC) to detect the expression of MUC1, MUC2, and MUC5AC in resected PDAC specimens from Shanghai Cancer Center, Fudan University (FUSCC, n = 427 ) and obtained the corresponding clinical statistical data for retrospective study. Kaplan-Meier methods and Mantel-Cox tests were used to compare the survival curves, and the Cox regression model was employed for multivariate analyses to determine the independent risk factors. Survival analysis was also performed in the Queensland Centre for Medical Genomics (QCMG, n = 70 ) PDAC cohort to verify the conclusion. Results. Both the FUSCC cohort and the QCMG cohort demonstrated that MUC1 absence was significantly correlated with worse overall survival (OS). The presence of MUC2 showed marginal significance in predicting shorter OS of PDAC patients, while MUC5AC had no prognostic value. In the FUSCC cohort, MUC1 absence was associated with increased proportion of stage III PDAC ( p = 0.011 ), and MUC1 absence and MUC2 presence were associated with tumour perineural aggression ( p = 0.011 and p = 0.030 , respectively). Multivariable adjusted hazard ratios (HRs) for mortality of MUC1 and MUC2 were 0.492 (95% CI: 0.274-0.883, p = 0.017 ) and 1.596 (95% CI: 1.061-2.401, p = 0.025 ), respectively. Conclusions. MUC1 absence or MUC2 presence is independently associated with poor OS among patients with resectable PDAC. MUC5AC absence tended to be associated with short-term death.

Relationship between expression of MUC4 in pancreatic cancer and clinical factors

Clinicopathological and Prognostic Significance of MUC4 Expression in Cancers: Evidence from Meta-Analysis.

Integrated Bioinformatics Analysis and Clinical Validation Reveals That High Expression of Mucin 1 in Intrahepatic Cholangiocarcinoma Predicts Recurrence after Curative Resection.

Integrative Analysis of MUC4 to Prognosis and Immune Infiltration in Pan-Cancer: Friend or Foe?

The relationship of expression of p53,p21,Ki-67 and VEGF and bladder cancer stage,grade and prognosis

Expression of Plk1 and MUC4 Gene in Pancreatic Carcinoma and Their Clinical Significance

B7-H4 is A Prognostic Biomarker for Poor Survival in Patients with Pancreatic Cancer

The Clinicopathological Significance of MRP Expression in Pancreatic Carcinoma

MUC4 is a Novel Mediator in H. Pylori Infection-Related Pancreatic Cancer

Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma.

Overexpressions of DLL4 and CD105 Are Associated with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma

The Clinical Utility of CA125/MUC16 in Pancreatic Cancer: A Consensus of Diagnostic, Prognostic and Predictive Updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)

Expressions and Clinical Significances of CXCR4 and β-catenin in Pancreatic Cancer

Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma

Prognostic significance of B7-H4 expression in matched primary pancreatic cancer and liver metastases.

Strongly Positive Expression of MUC1 and Its Relationship with Prognosis in Different Immunophenotypes of Breast Cancer Tissues

Expression of PSTAT3 and VEGF in pancreatic carcinoma and its clinical significance

Evaluation of Serum MUC5AC in Combination with CA19-9 for the Diagnosis of Pancreatic Cancer

Expression and clinical significance of SFRP4 in pancreatic ductal adenocarcinoma

Increased expression of MUC3A is associated with poor prognosis in localized clear-cell renal cell carcinoma.

Membranous co-expression of EpCAM and CD 44 s predicts poor prognosis in pancreatic cancer patients